Ambrx Biopharma — Investor Presentation (April 2023)
32 slides from Ambrx Biopharma's investor presentation, Apr 10, 2023
Slide 1: Corporate Presentation April 2023
Exhibit 99.1 Corporate Presentation April 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as
Slide 3: Antibody Drug Conjugates (ADCs) – Targeted Cancer Cell Killing
Antibody Drug Conjugates (ADCs) – Targeted Cancer Cell Killing Design ADCs Antibody Drug Conjugates (ADCs) are composed of 1) a cancer killing chemotherapeutic payload, 2) an antibody-targeting a cancer cell and 3) a linker connecting the antibody to the payload Problem ADCs that have weak linkage/c
Slide 4: Ambrx: Multiple Potential Value Drivers
Ambrx: Multiple Potential Value Drivers Two Antibody Drug Conjugate (ADC) Programs Delivering Data in 2023 ARX517 Anti-PSMA ADC: ARX788 Anti-HER2 ADC: Safety and efficacy data focusing on prostate Safety and efficacy data focusing on breast cancer cancer expected this year from APEX-01, expected thi
Slide 5: Ambrx Oncology Pipeline
Ambrx Oncology Pipeline Candidate Indications Trial Setting (Name) Preclinical Phase 1 Phase 2 Next Anticipated Milestone(s) Ambrx Sponsored Oncology Programs Neo Adjuvant BC I-SPY 2.2 Complete enrollment Preliminary data update – 2024 HER2+ mBC post- ARX788 Breast-03 TM ENHERTU Initiate post-ENHERT
Slide 6: Anticipated 2023 Clinical Milestones
Anticipated 2023 Clinical Milestones ARX517 ARX517 ARX788 ARX788 Anti-PSMA ADC Anti-PSMA ADC Anti-HER2 ADC Anti-HER2 ADC Pan-Tumor-01 APEX-01 Phase1 Pre-clinical data Initiate signal- ARX305 ARX305 preliminary data to be preliminary data to and TIP poster for finding study in Anti-CD70 ADC Anti-CD70
Slide 7: ADC Golden Age, Pfizer-Seagen $43B Buyout at a 20X Revenue Multiple
ADC Golden Age, Pfizer-Seagen $43B Buyout at a 20X Revenue Multiple Given the difficulty in developing a biosimilar, ADCs are a therapeutic modality that command a significant premium Other examples include: • Gilead’s acquisition of Immunomedics for $21B (2021) • Multi-billion Daiichi Sankyo and As
Slide 8: ARX517 Anti-PSMA ADC for Prostate and Other Cancers
ARX517 Anti-PSMA ADC for Prostate and Other Cancers
Slide 9: ARX517 is the Only ADC Targeting PSMA in Prostate Cancer
ARX517 is the Only ADC Targeting PSMA in Prostate Cancer Created with proprietary SAA technology AS269 • Fully humanized anti-PSMA monoclonal antibody (mAb) produced in CHO cells with site-specific incorporation of SAA for conjugation • Contains two (2) drug-linkers (AS269, a tubulin polymerization
Slide 10: ARX517 Addresses Stability Issues of Prior ADCs Targeting PSMA
ARX517 Addresses Stability Issues of Prior ADCs Targeting PSMA Name PSMA-ADC MLN-2704 MEDI-3726 ARX517 Company Progenics, Seagen Millenium/Takeda MediImmune, ADCT Ambrx Antibody fully human IgG1 J591 (humanized) J591 (humanized) J591 (humanized) Payload MMAE DM1 PBD dimer (SG3199) AS269 Payload cell
Slide 11: Ambrx's Proprietary Site-Specific Conjugation Designed to Produce Stable, Homogenous ADCs
Ambrx’s Proprietary Site-Specific Conjugation Designed to Produce Stable, Homogenous ADCs Ambrx’s SAA Conjugation Cysteine Conjugation Lysine Conjugation 80 Sites 32 Sites 2 Selected Sites SAA = Synthetic Amino Acid Maximum tolerated dose Maximum tolerated dose Maximum tolerated dose Less Narrow The
Slide 12: ARX517 - APEX-01 Phase 1 Trial Design
Eligibility Criteria ARX517 - APEX-01 Phase 1 Trial Design Must have had a least two We are here 2.9 mg/kg C8 FDA approved treatments for Dose Escalation prostate cancer one of the Q3W Dosing, i3+3 Design 2.4 mg/kg C7 (16-36 Adult Patients) following: 2.0 mg/kg C6 - PSA progression by a MTD or RP2D
Slide 13: The Case for ARX517 in mCRPC
The Case for ARX517 in mCRPC PSMA is highly expressed (89%) in metastatic castration resistant prostate cancer (mCRPC), as well as neovasculature of various solid tumors PSMA is a clinically validated target and an established market for mCRPC ® • PLUVICTO has validated the PMSA as an effective pros
Slide 14: ARX788 Anti HER2 ADC for HER2+ Metastatic Breast Patients in Post ENHERTU Settings
ARX788 Anti HER2 ADC for HER2+ Metastatic Breast Patients in Post ENHERTU Settings
Slide 15: ARX788 - Potential to Become ADC of Choice for Post-ENHERTU Patients
ARX788 - Potential to Become ADC of Choice for Post-ENHERTU Patients Fully humanized anti-HER2 mAb incorporated a synthetic amino acid at the optimized location on each of the two heavy chains to enable AS269 precision conjugation • DAR=2: Contains two (2) drug-linkers (AS269, a tubulin polymerizati
Slide 16: ENHERTU Changed the Breast Cancer ADC Landscape, but Patients Progress
ENHERTU Changed the Breast Cancer ADC Landscape, but 24.2% of Patients on ENHERTU Progress within 12 Months Lack of post-ENHERTU data supporting the effectiveness of KADCYLA and/or ® TUKYSA potentially creates a new large market opportunity with no standard of care https://www.thelancet.com/journals
Slide 17: Breast-01 (China) and PanTumor-01 (US/AU)
Breast-01 (China) and PanTumor-01(US/AU) † Confirmed ORR with ARX788 in patients whose disease is Breast-01 resistant or refractory to prior HER2 treatment (trastuzumab, 69 adult patients in China, ORR was 65.5%, DCR was 100% † ADCs, TKIs, and bispecific antibodies) and the median PFS was 17.02 mont
Slide 18: Breast-01 Demonstrated ARX788 Has Competitive Activity in HER2+ mBC ADC Landscape
Breast-01 Demonstrated ARX788 Has Competitive Activity Potential in the HER2+ mBC ADC Landscape HER2+ ADCs in Breast Cancer Efficacy Landscape* KADCYLA ENHERTU ENHERTU ARX788** RC48*** SYD985 (TDM1) (T-DXd) (T-DXd) Pop 2L 2L 3L Median 5L Median 4L 3L ORR 35.0% 78.5% 69.7% 65.5% 41% 27.8% DOR 23.8m 3
Slide 19: Breast-02 Pivotal Phase 3 Study of ARX788 Achieved Positive Results
Breast-02 Pivotal Phase 3 Study of ARX788 for the Treatment of HER2+ mBC Achieved Positive Results • Breast-02 is a randomized, controlled, pivotal Phase 3 clinical trial of ARX788 for the treatment of HER2+ patients with locally advanced or mBC in China • The study enrolled 441 HER2+ BC patients wh
Slide 20: ARX788 Provided a Clinical Benefit to Post KADCYLA (T-DM1) Patients
ARX788 Provided a Clinical Benefit to Post KADCYLA (T-DM1) Patients Key Takeaways* r r A r s . Statistically significant reduction in tumor size in patients 0.00 0 previously treated with T-DM1 who had disease progression 0 4/7 patients also previously received HER2 TKI treatment 20 0 Confirmed (ORR
Slide 21: Summary of ARX788 Safety Data (All Cohorts)
Summary of ARX788 Safety Data (All Cohorts) ARX788 (All Treated Population) Number of patients (%) Breast-01 Gastric-01 Pan-Tumor-01 (N=67) (N=69) (N=30) All AEs (regardless of causality) ( 00 61 (91.0%) 29 (96.7%) Treatment-related AEs (any grade) 67 (97.1%) 48 (71.6%) 28 (93.3%) All A s ≥ Grade
Slide 22: Systemic Toxicity: ARX788 Significantly Lower than ENHERTU
Systemic Toxicity: ARX788 (Breast Cancer and Pan-tumor) is Significantly Lower than ENHERTU (USPI)* ARX788 (1.5 mg/kg Breast cancer, Pan-Tumor population) ENHERTU (5.4 mg/kg)* Number of patients (%) Number of patients (%) Breast-01 (N=29) Pan tumor-01 (N=17) N=234 mBC All Grades Grade 3 or 4 All Gra
Slide 23: Mechanisms to Potentially Overcome Resistance to ENHERTU
Mechanisms to Potentially Overcome Resistance to ENHERTU Even in low HER2 target environment, ARX ’s engineered stability designed to ensure that it always delivers a fully loaded ADC sufficient to kill the cancer cell ENHERTU treatment can lead to reduction of HER2 target The payload of ARX788 is E
Slide 24: Rationale for Planned Phase Study of ARX788 in HER2+ mBC post-ENHERTU
Rationale for Planned Phase 2 Study of ARX788 in HER2+ mBC post-ENHERTU • Completed study Breast-01 (Phase 1) demonstrated robust response rate HER2+ metastatic breast cancer (mBC) in China and encouraging responses observed in Pan-Tumor-01 in the Amend existing Breast-03 US protocol to conduct a sm
Slide 25: Post-ENHERTU Market Could Be a Billion Dollar Opportunity
Post-ENHERTU Market Could Be a Billion Dollar Opportunity Assuming price is in line with TRODELVY 01 Estimated drug treated patients in 3L+ (~$25,000 for 4 wks) and similar PFS (~ 6 mo) equates to $150,000 per patient per course (3L or later) HER2+ BC: ~10,000 to >14,000, depending on source • 9,800
Slide 26: ARX788 Selected for Inclusion in I-SPY 2.2
ARX788 Selected for Inclusion in Prestigious I-SPY 2.2 A Phase 2 Trial to Treat HER2-Positive Breast Cancer in the Neoadjuvant Setting The adaptive trial assesses developing targeted agents to combine them with less toxic chemotherapeutic regimens or to completely replace cytotoxic chemotherapy ARX7
Slide 27: Financial Information Highlights
Financial Information Highlights Financial Information Cash, cash equivalents and investments as of 12/31/22: $101.3 MM Additional Cash Raised via ATM (Q1 2023): $78 MM Outstanding Shares (ADS*): 55.2 MM Clean Balance Sheet: No outstanding warrants or debt AMAM (NASDAQ) (March 20, 2023) Market Capit
Slide 28: Ambrx Leadership
Ambrx Leadership Shawn Zhang, PhD Ying Buechler, PhD Sandra Aung, PhD D ni O’ nn r, JD Sonja Nelson, CPA Chief Scientific Officer Chief Technology Officer Executive VP, Head of Clinical CEO and President CFO & COO AMBRX | Corporate Presentation 28
Slide 29: Appendix: Preclinical Pipeline and Other Programs
Appendix: Preclinical Pipeline and Other Programs Engineered Precision Biologics & Site-Specific Conjugation
Slide 30: Ambrx Preclinical Oncology Pipeline and Non-Oncology Programs
Ambrx Preclinical Oncology Pipeline and Non-Oncology Programs Candidate Indications Preclinical Phase 1 Phase 2 Key Highlights TROP2 is over-expressed in a variety of solid tumors. ARX ’s payload with differentiated MOA Numerous Cancer Types may address potential resistance to TOPOi ADCs. Stable lin
Slide 31: Engineered Precision Biologics – EPBs
Engineered Precision Biologics – EPBs ENGINEERED PRECISION BIOLOGICS Engineering proteins in Precise site-selection of a Biologics, which include a living cells, both bacterial stable and predictable wide variety of formats and mammalian, by attachment point in the (mAbs, cytokines, CD3 incorporatin
Slide 32: Ambrx's Proprietary Site-Specific Conjugation Produces Highly Stable and Homogenous ADCs
Ambrx’s Proprietary Site-Specific Conjugation Produces Highly Stable and Homogenous ADCs Expanded genetic code creates engineered proteins by site-specifically incorporating SAAs Enables precise modification and orthogonal chemistry for stable conjugation Enables novel drug design and potential wide